{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:58:37Z","timestamp":1790521117174,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,25]]},"DOI":"10.1182\/blood.2020007994","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T20:58:29Z","timestamp":1600203509000},"page":"1124-1129","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma"],"prefix":"10.1182","volume":"137","author":[{"given":"Paolo","family":"Strati","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph J.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-2260","authenticated-orcid":false,"given":"Sheryl","family":"Forbes","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3564-8697","authenticated-orcid":false,"given":"Maria A.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-4914","authenticated-orcid":false,"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"suppl 15","key":"2021022516234675400_B1","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2017.35.15_suppl.7501","article-title":"Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study","volume":"35","author":"Rummel","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2021022516234675400_B2","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021022516234675400_B3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2021022516234675400_B4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2021022516234675400_B5","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"2021022516234675400_B6","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"2021022516234675400_B7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2021022516234675400_B8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas [published correction appears in J Clin Oncol. 2000;18(11):2351]","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021022516234675400_B9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"27","key":"2021022516234675400_B10","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021022516234675400_B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"27","key":"2021022516234675400_B12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"34","key":"2021022516234675400_B13","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2021022516234675400_B14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/bjh.16414","article-title":"Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy","volume":"189","author":"Menter","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2021022516234675400_B15","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2021022516234675400_B16","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1080\/10428194.2020.1716221","article-title":"Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL","volume":"61","author":"Strati","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"9759","key":"2021022516234675400_B17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"2021022516234675400_B18","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/annonc\/mdt562","article-title":"The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)","volume":"25","author":"Luminari","year":"2014","journal-title":"Ann Oncol"},{"issue":"23","key":"2021022516234675400_B19","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"35","key":"2021022516234675400_B20","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021022516234675400_B21","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/jco.2015.33.15_suppl.8504","article-title":"Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts)","volume":"33","author":"Sargent","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021022516234675400_B22","article-title":"Results of a phase II study of obinutuzumab in combination with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL) [abstract]","volume":"134","author":"Nastoupil","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021022516234675400_B23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/blood-2018-99-113721","article-title":"Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: an open label, phase II study [abstract]","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2021022516234675400_B24","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2021022516234675400_B25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2021022516234675400_B26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-128096","article-title":"Phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory follicular lymphoma [abstract]","volume":"134","author":"Morschhauser","year":"2019","journal-title":"Blood"},{"issue":"26","key":"2021022516234675400_B27","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","article-title":"Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18\u2009018 patients and 1149 events","volume":"115","author":"Caruso","year":"2010","journal-title":"Blood"},{"issue":"33","key":"2021022516234675400_B28","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021022516234675400_B29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/8\/1124\/1800880\/bloodbld2020007994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/8\/1124\/1800880\/bloodbld2020007994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T17:38:44Z","timestamp":1614274724000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/8\/1124\/463764\/Long-term-follow-up-of-lenalidomide-and-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020007994","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]}}}